Astmabehandling i almen praksis

Victor Behrendt; Ole Hilberg; Vibeke Bakker; Charlotte Suppli Ulrik; Niels Bjerring; Anders Løkke

Astmabehandling i almen praksis

Translated title of the contribution: Asthma treatment in general practice

Victor Behrendt, Ole Hilberg, Vibeke Bakker, Charlotte Suppli Ulrik, Niels Bjerring, Anders Løkke

Research output: Contribution to journal › Journal article › Research › peer-review

16 Downloads (Pure)

Abstract

This review describes the current Danish guidelines for inhaled asthma treatment. Monotherapy with short-acting beta-agonists (SABA) taken when needed is no longer recommended in asthma therapy for adults due to safety concerns. The recommended first-line treatment is now inhaled corticosteroids (ICS) taken with formoterol or ICS taken with SABA. The choice of inhaler can have a significant impact on compliance and symptom control, and an individualized approach is therefore needed. Biological treatment may be an alternative to oral corticosteroids in selected patient groups.

Translated title of the contribution	Asthma treatment in general practice
Original language	Danish
Article number	V03210221
Journal	Ugeskrift for Laeger
Volume	184
Issue number	2
Number of pages	8
ISSN	0041-5782
Publication status	Published - 10 Jan 2022

Access to Document

FulltextFinal published version, 740 KBLicence: CC BY-NC-ND

https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2022-01/v03210221_web.pdf

Cite this

@article{1711b5a37b864145b9b9d531418de2e1,

title = "Astmabehandling i almen praksis",

abstract = "This review describes the current Danish guidelines for inhaled asthma treatment. Monotherapy with short-acting beta-agonists (SABA) taken when needed is no longer recommended in asthma therapy for adults due to safety concerns. The recommended first-line treatment is now inhaled corticosteroids (ICS) taken with formoterol or ICS taken with SABA. The choice of inhaler can have a significant impact on compliance and symptom control, and an individualized approach is therefore needed. Biological treatment may be an alternative to oral corticosteroids in selected patient groups.",

keywords = "Administration, Inhalation, Adrenal Cortex Hormones/therapeutic use, Adult, Anti-Asthmatic Agents/adverse effects, Asthma/drug therapy, Drug Therapy, Combination, Ethanolamines/therapeutic use, Formoterol Fumarate/therapeutic use, General Practice, Humans",

author = "Victor Behrendt and Ole Hilberg and Vibeke Bakker and Ulrik, {Charlotte Suppli} and Niels Bjerring and Anders L{\o}kke",

year = "2022",

month = jan,

day = "10",

language = "Dansk",

volume = "184",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "2",

}

TY - JOUR

T1 - Astmabehandling i almen praksis

AU - Behrendt, Victor

AU - Hilberg, Ole

AU - Bakker, Vibeke

AU - Ulrik, Charlotte Suppli

AU - Bjerring, Niels

AU - Løkke, Anders

PY - 2022/1/10

Y1 - 2022/1/10

N2 - This review describes the current Danish guidelines for inhaled asthma treatment. Monotherapy with short-acting beta-agonists (SABA) taken when needed is no longer recommended in asthma therapy for adults due to safety concerns. The recommended first-line treatment is now inhaled corticosteroids (ICS) taken with formoterol or ICS taken with SABA. The choice of inhaler can have a significant impact on compliance and symptom control, and an individualized approach is therefore needed. Biological treatment may be an alternative to oral corticosteroids in selected patient groups.

AB - This review describes the current Danish guidelines for inhaled asthma treatment. Monotherapy with short-acting beta-agonists (SABA) taken when needed is no longer recommended in asthma therapy for adults due to safety concerns. The recommended first-line treatment is now inhaled corticosteroids (ICS) taken with formoterol or ICS taken with SABA. The choice of inhaler can have a significant impact on compliance and symptom control, and an individualized approach is therefore needed. Biological treatment may be an alternative to oral corticosteroids in selected patient groups.

KW - Administration, Inhalation

KW - Adrenal Cortex Hormones/therapeutic use

KW - Adult

KW - Anti-Asthmatic Agents/adverse effects

KW - Asthma/drug therapy

KW - Drug Therapy, Combination

KW - Ethanolamines/therapeutic use

KW - Formoterol Fumarate/therapeutic use

KW - General Practice

KW - Humans

M3 - Tidsskriftartikel

C2 - 35023469

VL - 184

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 2

M1 - V03210221

ER -